查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1638743

下一代癌症诊断市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Next Generation Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 144 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球下一代癌症诊断市场到2023 年将达到155 亿美元，预计2024 年至2032 年将以10% 的复合年增长率增长。个体遗传和资料定制治疗方案。先进的诊断技术，包括新一代定序 (NGS) 和液体活检，对于识别基因突变和特定癌症生物标记至关重要。这些功能增强了早期检测并优化了标靶治疗选择。

下一代癌症诊断引入了先进的工具和技术，能够实现精确、早期检测和个人化的癌症分析。这些进步改善了疾病监测和风险评估，从而可以精确选择标靶治疗。透过关注肿瘤独特的遗传、分子和细胞特征，在精准医疗实现更好临床结果和更有效治疗的潜力的推动下，该市场正在引领癌症治疗领域的一场革命。

市场分为产品和服务，其中产品细分市场占据重要份额，预计在预测期内将以 9.8% 的复合年增长率成长。该部分包括仪器、套件和消耗品，这些都是诊断准确性和效率所必需的。对广泛应用于医院、实验室和研究机构的先进测序平台、PCR 机器和成像设备的需求很高，对市场收入做出了巨大贡献。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 155 亿美元
预测值 362 亿美元
复合年增长率 10%

从技术上讲，NGS 领域的下一代癌症诊断市场由于能够快速、准确地提供详细的基因组见解，到 2023 年将占据 32.5% 的份额。 NGS 在识别基因突变和生物标记方面的作用对于早期癌症检测和个人化治疗至关重要，随着癌症盛行率的不断上升、NGS 的创新和成本的降低推动了采用。

在美国，到 2032 年，下一代癌症诊断市场将以 9.5% 的复合年增长率成长。着名的生物技术和製药公司的存在、政府对癌症研究的大力支持以及公众对早期检测意识的提高，巩固了美国在这个快速发展的领域的地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症盛行率上升
      • 诊断技术不断进步
      • 增加对癌症研究的投资
      • 提高认识和筛检计划
    • 产业陷阱与挑战
      • 先进诊断技术的高成本
      • 严格的法规和漫长的审核流程
  • 成长潜力分析
  • 未来市场趋势
  • 技术景观
  • 定价分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品和服务划分，2021 - 2032 年

  • 主要趋势
  • 产品
    • 仪器仪表
    • 套件和消耗品
  • 服务

第 6 章：市场估计与预测：按技术划分，2021 - 2032 年

  • 主要趋势
  • 新一代定序 (NGS)
  • 聚合酶炼式反应 (PCR)
  • DNA微阵列
  • 多路復用
  • 其他技术

第 7 章：市场估计与预测：按癌症类型，2021 - 2032 年

  • 主要趋势
  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 子宫颈癌
  • 肝癌
  • 其他癌症类型

第 8 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 筛检和早期发现
  • 预测和监测
  • 治疗选择
  • 復发监测
  • 其他应用

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断实验室
  • 学术研究机构
  • 其他最终用户

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：公司简介

  • Agilent
  • Almac
  • Bio-Rad Laboratories
  • Exact Sciences
  • F. Hoffmann-La Roche
  • GenScript
  • Guardant Health
  • Illumina
  • Karkinos Healthcare
  • Qiagen
  • Koninklijke Philips
  • Thermo Fisher Scientific
简介目录
Product Code: 12160

The Global Next Generation Cancer Diagnostics Market reached USD 15.5 billion in 2023 and is projected to grow at a 10% CAGR from 2024 to 2032. The surge in demand is primarily fueled by the shift towards personalized medicine, which tailors treatments based on individual genetic and molecular data. Advanced diagnostic technologies, including next-generation sequencing (NGS) and liquid biopsy, are central to identifying genetic mutations and specific cancer biomarkers. These capabilities enhance early detection and optimize targeted therapy selection.

Next-generation cancer diagnostics introduce advanced tools and techniques enabling precise, early detection and personalized cancer analysis. These advancements improve disease monitoring and risk assessment, allowing for the refined selection of targeted therapies. By focusing on the unique genetic, molecular, and cellular characteristics of tumors, this market is leading a revolution in cancer care, driven by precision medicine's potential to achieve better clinical outcomes and more effective treatment.

The market is divided into products and services, with the products segment taking a significant share and expected to grow at a 9.8% CAGR over the forecast period. This segment includes instruments and kits & consumables, all essential for diagnostic accuracy and efficiency. Demand is high for advanced sequencing platforms, PCR machines, and imaging devices used widely across hospitals, laboratories, and research institutions, contributing significantly to market revenue.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$15.5 Billion
Forecast Value$36.2 Billion
CAGR10%

Technologically, the next generation cancer diagnostics market from the NGS segment held 32.5% share in 2023 due to its ability to provide detailed genomic insights quickly and accurately. NGS's role in identifying genetic mutations and biomarkers is vital for early cancer detection and personalized treatment, with growing cancer prevalence, NGS innovations, and decreasing costs driving adoption.

In the U.S., the next-generation cancer diagnostics market is set to grow at a 9.5% CAGR through 2032. The country leads the market due to its advanced healthcare infrastructure, substantial R&D investments, and emphasis on innovation. The presence of prominent biotechnology and pharmaceutical firms, strong government backing for cancer research, and increased public awareness of early detection reinforces the U.S.'s position in this rapidly evolving field.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer
      • 3.2.1.2 Growing advancement in diagnostic technologies
      • 3.2.1.3 Increased investments in cancer research
      • 3.2.1.4 Growing awareness and screening programs
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High costs of advanced diagnostics technologies
      • 3.2.2.2 Stringent regulations and lengthy approval processes
  • 3.3 Growth potential analysis
  • 3.4 Future market trends
  • 3.5 Technology landscape
  • 3.6 Pricing analysis
  • 3.7 Regulatory landscape
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product & Service, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Products
    • 5.2.1 Instruments
    • 5.2.2 Kits & consumables
  • 5.3 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Next-generation sequencing (NGS)
  • 6.3 Polymerase chain reaction (PCR)
  • 6.4 DNA microarrays
  • 6.5 Multiplexing
  • 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Breast cancer
  • 7.3 Lung cancer
  • 7.4 Colorectal cancer
  • 7.5 Prostate cancer
  • 7.6 Cervical cancer
  • 7.7 Liver cancer
  • 7.8 Other cancer types

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Screening and early detection
  • 8.3 Prognostics and monitoring
  • 8.4 Therapy selection
  • 8.5 Recurrence monitoring
  • 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals & clinics
  • 9.3 Diagnostic laboratories
  • 9.4 Academic & research institutions
  • 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Agilent
  • 11.2 Almac
  • 11.3 Bio-Rad Laboratories
  • 11.4 Exact Sciences
  • 11.5 F. Hoffmann-La Roche
  • 11.6 GenScript
  • 11.7 Guardant Health
  • 11.8 Illumina
  • 11.9 Karkinos Healthcare
  • 11.10 Qiagen
  • 11.11 Koninklijke Philips
  • 11.12 Thermo Fisher Scientific